MAPPING PEPTIDE BINDING SITES OF SP & SK RECEPTORS

SP 肽结合位点图谱

基本信息

  • 批准号:
    6206404
  • 负责人:
  • 金额:
    $ 0.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-07-01 至 2000-06-30
  • 项目状态:
    已结题

项目摘要

Electrospray (ESI) and matrix-assisted laser desorption/ionization (NLALDI) mass spectrometry, in combination with proteolyic digestion and BPLC separation, have been used to verify the cDNA-predicted amino acid sequence of chicken type II collagen. The type II collagen molecule is composed of three identical polypeptide chains [alpha, (11) chains] intertwined in a triple helix. The single triple helical domain comprises about 96% of the amino acid sequence and consists of repeating tripeptides of the form glycine-X-Y (G-X-Y). The helical domain is flanked on both the N-terminal and C-terminal ends by short non-helical domains known as telopeptides. Themolecular weight for the unmodified chicken type 11 collagen triple helix predicted from the cDNA sequence is 294 kDa. Posttranslational modifications occur at numerous sites; the best studied are hydroxylation of prolines and lysines in the Y position of the G-X-Y sequence, glycosylation of hydroxylated lysines, and interhelical cross-linkages between lysines and hydroxylysines. Mass spectrometric analysis of this protein is very challenging because several factors produce heterogeneity. Incomplete modification at the large number of potential sites for post-translational modifications produces a variety of forms. During the solubilization of type 11 collagen from chicken sterna by pepsin digestion, the C-terminal telopeptide may be cleaved at several different points, producing additicrnal heterogeneity. The digestion may also generate "tags" from the crosslinked peptides that are attached to the main chain. Chicken type 11 collagen hasbeen heat denatured and digested with endoproteinase Lys-C. The Lys-C peptides were separated by reversed-phase FIPLC, collected and examined by MALDI-TOF MS and ESI MS. A total of 131 different peptides with molecular weights ranging from 711 Da to 14,027 Da have been identified to date. MS/MS analyses and secondary digestions have been performed to determine peptide sequence and to locate modification sites within a peptide. Our mass spectrometric analysis has identified numerous sites of hydroxylation and glycosylation and has identified several C-termini. This analysis has enabled us to confirm most of the residues predicted from the cDNA sequence and to correct a few misassignments The results show a high degree of heterogeneity in hydroxylation and glycosylation with attendant shifts in chromatographic behavior.
电喷雾(ESI)和基质辅助激光解吸/电离 (NLALDI)质谱,结合蛋白水解消化 和BPLC分离,已被用来验证cDNA预测的氨基酸 鸡II型胶原蛋白的酸性序列。 II型胶原蛋白 分子由三条相同的多肽链组成[α, (11)链]在三重螺旋中缠绕。 单三螺旋 结构域包含约96%的氨基酸序列,并且由以下组成: 甘氨酸-X-Y(G-X-Y)形式的重复三肽。 螺旋 结构域在N-末端和C-末端上都侧接短的 称为端肽的非螺旋结构域。 分子量 未修饰的鸡11型胶原蛋白三螺旋预测从 cDNA序列为294 kDa。 翻译后修饰发生在 在许多位点;研究得最好的是脯氨酸的羟基化, G-X-Y序列的Y位置上的赖氨酸, 羟基化赖氨酸和赖氨酸之间的螺旋间交联 和羟基赖氨酸。 该蛋白质的质谱分析是 非常具有挑战性,因为有几个因素会产生异质性。 在大量的潜在地点进行不完全的修改, 翻译后修饰产生多种形式。 期间 胃蛋白酶对鸡胸骨11型胶原蛋白增溶作用 消化后,C-末端端肽可以在几个位点被切割, 不同的点,产生额外的异质性。 消化 也可以从交联肽产生“标签”, 附在主链上。 鸡11型胶原蛋白已被加热 变性并用内切蛋白酶Lys-C消化。 Lys-C肽 通过反相HPLC分离,收集并通过HPLC检测。 MALDI-TOF MS和ESI MS。 分子量范围为711 Da至14,027 Da, 识别日期。 MS/MS分析和二级数字化已被 进行测定肽序列和定位修饰 肽内的位点。 我们的质谱分析 鉴定了许多羟基化和糖基化位点, 鉴定了几个C-末端。 通过分析我们可以确认 从cDNA序列预测的大多数残基, 结果显示,在不同的实验条件下, 羟基化和糖基化,伴随着 色谱行为

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NORMAN D BOYD其他文献

NORMAN D BOYD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NORMAN D BOYD', 18)}}的其他基金

MAPPING PEPTIDE BINDING SITES OF SP & SK RECEPTORS
SP 肽结合位点图谱
  • 批准号:
    6478933
  • 财政年份:
    2000
  • 资助金额:
    $ 0.62万
  • 项目类别:
MAPPING PEPTIDE BINDING SITES OF SP & SK RECEPTORS
SP 肽结合位点图谱
  • 批准号:
    6345209
  • 财政年份:
    2000
  • 资助金额:
    $ 0.62万
  • 项目类别:
MAPPING PEPTIDE BINDING SITES OF SP & SK RECEPTORS
SP 肽结合位点图谱
  • 批准号:
    6123247
  • 财政年份:
    1998
  • 资助金额:
    $ 0.62万
  • 项目类别:
MAPPING PEPTIDE BINDING SITES OF SP & SK RECEPTORS
SP 肽结合位点图谱
  • 批准号:
    6254129
  • 财政年份:
    1997
  • 资助金额:
    $ 0.62万
  • 项目类别:
MAPPING THE PEPTIDE-BINDING SITES OF SP AND SK RECEPTORS
SP 和 SK 受体的肽结合位点图谱
  • 批准号:
    2269259
  • 财政年份:
    1992
  • 资助金额:
    $ 0.62万
  • 项目类别:
SP RECEPTOR BINDING SITES FOR AGONISTS AND ANTAGONISTS
激动剂和拮抗剂的 SP 受体结合位点
  • 批准号:
    2037614
  • 财政年份:
    1992
  • 资助金额:
    $ 0.62万
  • 项目类别:
SP RECEPTOR BINDING SITES FOR AGONISTS AND ANTAGONISTS
激动剂和拮抗剂的 SP 受体结合位点
  • 批准号:
    2839354
  • 财政年份:
    1992
  • 资助金额:
    $ 0.62万
  • 项目类别:
MAPPING THE PEPTIDE-BINDING SITES OF SP AND SK RECEPTORS
SP 和 SK 受体的肽结合位点图谱
  • 批准号:
    2269260
  • 财政年份:
    1992
  • 资助金额:
    $ 0.62万
  • 项目类别:
SP RECEPTOR BINDING SITES FOR AGONISTS AND ANTAGONISTS
激动剂和拮抗剂的 SP 受体结合位点
  • 批准号:
    2609645
  • 财政年份:
    1992
  • 资助金额:
    $ 0.62万
  • 项目类别:
MAPPING THE PEPTIDE BINDING SITES OF SP AND SK RECEPTORS
SP 和 SK 受体的肽结合位点图谱
  • 批准号:
    3418265
  • 财政年份:
    1992
  • 资助金额:
    $ 0.62万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.62万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.62万
  • 项目类别:
    Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
  • 批准号:
    10068495
  • 财政年份:
    2024
  • 资助金额:
    $ 0.62万
  • 项目类别:
    Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 0.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
  • 批准号:
    24K19850
  • 财政年份:
    2024
  • 资助金额:
    $ 0.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    $ 0.62万
  • 项目类别:
    Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
  • 批准号:
    489316
  • 财政年份:
    2023
  • 资助金额:
    $ 0.62万
  • 项目类别:
    Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    $ 0.62万
  • 项目类别:
    Fellowship
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
  • 批准号:
    23K14987
  • 财政年份:
    2023
  • 资助金额:
    $ 0.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
  • 批准号:
    10696749
  • 财政年份:
    2023
  • 资助金额:
    $ 0.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了